{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:40:47Z","timestamp":1791726047885,"version":"4.3.4"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,3]],"date-time":"2023-06-03T00:00:00Z","timestamp":1685750400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Tuberculosis and Other Mycobacterial Diseases"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.jctube.2023.100382","type":"journal-article","created":{"date-parts":[[2023,6,12]],"date-time":"2023-06-12T21:45:12Z","timestamp":1686606312000},"page":"100382","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Trends in tuberculosis clinicians\u2019 adoption of short-course regimens for latent tuberculosis infection"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7051-7414","authenticated-orcid":false,"given":"Pei-Jean I.","family":"Feng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Horne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan M.","family":"Wortham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolly J.","family":"Katz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jctube.2023.100382_b0005","doi-asserted-by":"crossref","unstructured":"Yuen CM, Kammerer JS, Marks K, et al. Recent Transmission of Tuberculosis \u2014 United States, 2011\u20132014. Sreevatsan S, editor. PLOS ONE. 2016 Apr 15;11(4):e0153728.","DOI":"10.1371\/journal.pone.0153728"},{"issue":"10","key":"10.1016\/j.jctube.2023.100382_b0010","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S1473-3099(17)30248-7","article-title":"Latent tuberculosis infection: the final frontier of tuberculosis elimination in the USA","volume":"17","author":"LoBue","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"11","key":"10.1016\/j.jctube.2023.100382_b0015","doi-asserted-by":"crossref","first-page":"e0140881","DOI":"10.1371\/journal.pone.0140881","article-title":"Tuberculosis Infection in the United States: Prevalence Estimates from the National Health and Nutrition Examination Survey, 2011\u20132012","volume":"10","author":"Miramontes","year":"2015","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.jctube.2023.100382_b0020","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1017\/S095026881100286X","article-title":"Modelling tuberculosis trends in the USA","volume":"140","author":"Hill","year":"2012","journal-title":"Epidemiol Infect"},{"key":"10.1016\/j.jctube.2023.100382_b0025","doi-asserted-by":"crossref","first-page":"4019","DOI":"10.1378\/chest.09-0394","article-title":"Latent TB infection treatment acceptance and completion in the United States and Canada","volume":"137","author":"Horsburgh","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jctube.2023.100382_b0030","unstructured":"Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society. MMWR Recomm Rep Morb Mortalality Wkly Rep Recomm. 2000 Jun 9;49(RR-6):1\u201351."},{"key":"10.1016\/j.jctube.2023.100382_b0035","unstructured":"Centers for Disease Control and Prevention (CDC), American Thoracic Society. Update: adverse event data and revised American Thoracic Society\/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection--United States, 2003. MMWR Morb Mortal Wkly Rep. 2003 Aug 8;52(31):735\u20139."},{"key":"10.1016\/j.jctube.2023.100382_b0040","unstructured":"Centers for Disease Control and Prevention (CDC). Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep. 2011 Dec 9;60(48):1650\u20133."},{"issue":"3","key":"10.1016\/j.jctube.2023.100382_b0045","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jamapediatrics.2014.3158","article-title":"Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid","volume":"169","author":"Villarino","year":"2015","journal-title":"JAMA Pediatr"},{"issue":"25","key":"10.1016\/j.jctube.2023.100382_b0050","doi-asserted-by":"crossref","first-page":"723","DOI":"10.15585\/mmwr.mm6725a5","article-title":"Update of recommendations for use of once-weekly isoniazid-rifapentine regimen to treat latent mycobacterium tuberculosis infection","volume":"67","author":"Borisov","year":"2018","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"10.1016\/j.jctube.2023.100382_b0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","article-title":"Guidelines for the treatment of latent tuberculosis infection: recommendations from the national tuberculosis controllers association and CDC, 2020","volume":"69","author":"Sterling","year":"2020","journal-title":"MMWR Recomm Rep"},{"issue":"23","key":"10.1016\/j.jctube.2023.100382_b0060","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1056\/NEJMoa1104875","article-title":"Three months of rifapentine and isoniazid for latent tuberculosis infection","volume":"365","author":"Sterling","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jctube.2023.100382_b0065","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1164\/rccm.200404-478OC","article-title":"Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months","volume":"170","author":"Menzies","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.jctube.2023.100382_b0070","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1473-3099(21)00145-6","article-title":"Comparison of three tests for latent tuberculosis infection in high-risk people in the USA: an observational cohort study","volume":"22","author":"Ho","year":"2022","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"10.1016\/j.jctube.2023.100382_b0075","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1001\/jama.300.4.405","article-title":"Tuberculosis among foreign-born persons in the United States","volume":"300","author":"Cain","year":"2008","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jctube.2023.100382_b0080","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1164\/rccm.201308-1480OC","article-title":"Persistent latent tuberculosis reactivation risk in United States immigrants","volume":"189","author":"Walter","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"10.1016\/j.jctube.2023.100382_b0085","doi-asserted-by":"crossref","first-page":"420","DOI":"10.7326\/M14-2082","article-title":"Effect of a culture-based screening algorithm on tuberculosis incidence in immigrants and refugees bound for the United States: a population-based cross-sectional study","volume":"162","author":"Liu","year":"2015","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.jctube.2023.100382_b0090","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.2105\/AJPH.2014.302287","article-title":"Postarrival tuberculosis screening of high-risk immigrants at a local health department","volume":"105","author":"Nuzzo","year":"2015","journal-title":"Am J Public Health"},{"issue":"14","key":"10.1016\/j.jctube.2023.100382_b0095","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1186\/1472-6963-14-469","article-title":"Factors affecting the uptake of new medicines: a systematic literature review","volume":"20","author":"Lubl\u00f3y","year":"2014","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"10.1016\/j.jctube.2023.100382_b0100","doi-asserted-by":"crossref","DOI":"10.1186\/1472-6963-12-56","article-title":"Adoption of new drugs by physicians: a survival analysis","volume":"12","author":"Garj\u00f3n","year":"2012","journal-title":"BMC Health Serv Res"},{"issue":"2","key":"10.1016\/j.jctube.2023.100382_b0105","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2165\/11532150-000000000-00000","article-title":"Disparities in combination drug therapy use in older adults with coronary heart disease: a cross-sectional time-series in a nationally representative US sample","volume":"27","author":"Tjia","year":"2010","journal-title":"Drugs Aging"},{"issue":"1_suppl","key":"10.1016\/j.jctube.2023.100382_b0110","doi-asserted-by":"crossref","first-page":"38S","DOI":"10.1177\/0033354920912710","article-title":"Policy implications of mathematical modeling of latent tuberculosis infection testing and treatment strategies to accelerate tuberculosis elimination","volume":"135","author":"Marks","year":"2020","journal-title":"Public Health Rep"}],"container-title":["Journal of Clinical Tuberculosis and Other Mycobacterial Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405579423000384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405579423000384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T07:38:22Z","timestamp":1762501102000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405579423000384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":22,"alternative-id":["S2405579423000384"],"URL":"https:\/\/doi.org\/10.1016\/j.jctube.2023.100382","relation":{},"ISSN":["2405-5794"],"issn-type":[{"value":"2405-5794","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Trends in tuberculosis clinicians\u2019 adoption of short-course regimens for latent tuberculosis infection","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jctube.2023.100382","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100382"}}